B淋巴细胞刺激因子的药学前景

The pharmaceutical prospect of B lymphocyte stimulator

B淋巴细胞刺激因子(BlyS)是肿瘤坏死因子(TNF)超家族的一名新成员,它与某些免疫疾病的致病机制密切相关。从BlyS的生物学结构和功能入手,阐述与其相关的免疫缺陷病、自身免疫疾病和淋巴瘤等免疫疾病,以及BlyS治疗性蛋白、BlyS蛋白拮抗物、放射性BlyS蛋白的临床应用前景。

BLyS is a novel human protein called B lymphocyte stimulator that belongs to the tumor necrosis factor （TNF） superfamily of cytokines. BLyS stimulates immune system cells called B cells to mature into plasma B cells, which produce antibodies. BLyS is recently shown to be critical for survival of normal B cells and has been found to be elevated in a number of immune disease models. The discovery of BLyS may lead to therapies for several diseases that involve B cells, including immune deficiencies, autoimmune disease and lymphoma. This review presents the several advanced therapeutic concepts based on the discovery of BLyS, including BLyS therapeutic protein, human monoclonal antibodies targeting BLyS and radiolabeled BLyS.